Peptide Vaccines for Hypertension and Diabetes Mellitus
AbstractVaccines are commonly used as a preventive medicine for infectious diseases worldwide; however, the trial for an amyloid beta vaccine against Alzheimer’s disease will open a new concept in vaccination. In case of therapeutic vaccines for cancer, their targets are usually specific antigens in cancer cells, allowing activated cytotoxic T cells (CTLs) to attach and remove the antigen-presenting cancer cells. In our therapeutic vaccines against hypertension, the target is angiotensin II (Ang II) and induced anti-Ang II antibodies could efficiently ameliorate high blood pressure. Similarly, we developed the therapeutic vaccine against DPP4 for diabetes mellitus. However, because Ang II or DPP4 is an endogenous hormone, we must avoid autoimmune disease induced by these vaccines. Therefore, our system was used to design a therapeutic vaccine that elicits anti-Ang II or DPP4 antibodies without CTL activation against Ang II or DPP4. In this review, we will describe our concept of therapeutic vaccines for hypertension and diabetes mellitus. View Full-Text
Share & Cite This Article
Nakagami, H.; Koriyama, H.; Morishita, R. Peptide Vaccines for Hypertension and Diabetes Mellitus. Vaccines 2014, 2, 832-840.
Nakagami H, Koriyama H, Morishita R. Peptide Vaccines for Hypertension and Diabetes Mellitus. Vaccines. 2014; 2(4):832-840.Chicago/Turabian Style
Nakagami, Hironori; Koriyama, Hiroshi; Morishita, Ryuichi. 2014. "Peptide Vaccines for Hypertension and Diabetes Mellitus." Vaccines 2, no. 4: 832-840.